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Background/Aims:  The  aim  of  this  study  was  to  investigate  poor  prognostic  factors  associated  with  a  near-fatal 
asthma  attack  following  patient  recovery. 
Methods: We  enrolled  68  patients  who  suffered  near-fatal  asthma  attacks  a nd we r e  a dmi t t e d t o t he  i n t e ns i v e  c a r e 
units of five university hospitals. The patients were divided into two groups. The first group was comprised of patients 
who discontinued oral corticosteroids within 6 months after being discharged from the hospital and who maintained a 
forced expiratory volume in 1 s (FEV1) ≥60% of the maximum or estimated values of the corresponding patients. The 
second group included patients who continued on oral corticosteroids for ≥6 months or who maintained a FEV1 <60%. 
Results:  In  patients  with  near-fatal  asthma,  factors  for  a  poor  prognosis  included  older  age  [48.47±3.53  vs. 
64.69±2.59  years,  p<0.05],  chronic  severe  asthma,  high  values  for  inflammation-related  laboratory  markers  (ESR, 
8.75±2.05 vs. 23.88±4.40 mm/h, p=0.004; CRP, 1.72±0.46 vs. 6.68±9.36 mg/dL, p<0.05), asthma exacerbated by 
pneumonia  (28.1  vs.  52.8%,  p<0.05),  and  relatively  low  nutritional  status  (albumin,  4.00±0.14  vs.  3.51±0.10  g/dL, 
p<0.05). 
Conclusions:  These  prognostic  factors  may  induce  irreversible  obstruction  of  the  airways  with  subsequent  acute 
exacerbation of asthma or the need for continual oral corticosteroids after being discharged from the hospital. Patients 
with  these  factors  should  be  treated  appropriately,  under  close  surveillance. 
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INTRODUCTION
Asthma is a serious worldwide public health concern
1). Some 
asthmatic patients present with complicating conditions such as 
hypercapnea (PaCO2, ≥45 mmHg), and some require mechani-
cal  ventilation  assistance.  This  type  of  asthma  exacerbation  is 
commonly  referred  to  as  near-fatal  asthma  (NFA),  severe 
life-threatening  asthma,  or  acute  severe  asthma.  The  classifi-
cation  system  established  by  the  Global  Initiative  for  Asthma 
categorizes  NFA  as  acute  severe  asthma  and  imminent 
respiratory  arrest;  the  British  Thoracic  Society  (BTS)  classifies 
NFA  as  acute  severe  asthma  and  life  threatening  asthma
2, 3). 
A c c o r d i n g  t o  o n e  s t u d y  c o m p a r i n g  p a t i e n t s  w h o  v i s i t e d  a n  
emergency  department  due  to  asthma  during  1996-2000  and 
those  who  were  admitted  during  2001-2003,  the  proportion  of 
patients  with  NFA  has  increased  over  time
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 Characteristic
All
(n=68)
Group  1
†
(n=32)
Group  2
‡
(n=36)
 p v a l u e
§
Age,  yr
Sex,  M:F
Smoking  status 
 N e v e r  s m o k e d
  Ex-smoker
 C u r r e n t  s m o k e r
Atopy
Duration  of  diagnosed  asthma
  >10  yr
  5-10  yr
 1 - 5  y r
 < 1  y r
  First  asthma  attack
Hospital  admissions  for  asthma
 I C U
  General  ward
  General  ward  within  1yr
Administration  of  anti-inflammatory  agent 
without  interruption
D u r i n g  3  m o  b e f o r e  a d m i s s i o n
  Oral  corticosteroid
  Inhaled  corticosteroid
  Beta-agonist
  Theophylline
During  2  wk  before  admission
  Oral  corticosteroid
  Inhaled  corticosteroid
  Beta-agonist
  Theophylline
56.94±2.37
35:33
(51.5:48.5)
43  (63.2)
12  (17.6)
13  (19.1)
28  (41.2)
21  (30.9)
19  (27.9)
18  (26.5)
7  (10.3)
3  (4.4)
38  (55.9)
10  (14.7)
34  (50.0)
16  (23.5)
23  (33.8)
16  (24.2)
23  (34.8)
37  (56.1)
21  (31.8)
15  (22.7)
18  (27.3)
35  (51.5)
20  (29.4)
48.47±3.53
14:18
(43.8:56.3)
20  (62.5)
4  (12.5)
8  (25.0)
14  (43.8)
7  (21.9)
11  (34.3)
8  (25.0)
4  (12.5)
2  (6.3)
16  (50.0)
4  (12.5)
15  (46.9)
7  (21.9)
6  (18.8)
3  (9.4)
10  (31.3)
17  (53.1)
6  (18.8)
4  (12.5)
5  (15.6)
16  (50.0)
6  (18.8)
64.69±2.59
21:15
(58.3:41.7)
23  (63.9)
8  (22.2)
5  (13.9)
14  (38.9)
14  (38.9)
8  (22.2)
10  (27.8)
3  (8.3)
1  (2.8)
22  (61.1)
6  (16.7)
19  (52.8)
9  (25.0)
17  (47.2)
13  (36.1)
13  (36.1)
20  (55.6)
15  (41.7)
11  (30.6)
14  (38.9)
19  (52.8)
14  (38.9)
<0.001
NS 
 
NS
NS
0.082
NS
NS
NS
NS
0.016
0.009
NS
NS
0.041
0.073
0.033
NS
0.069
*Values  given  as  means±SE  or  No.  (%),  unless  otherwise  indicated.  NS, not  significant.
†Group  1:  Patients  who  discontinued  oral  corticosteroids  within  6  months  after  being  discharged  from  the  hospital  and  whose  FEV1 
was  maintained  ≥60%  of  the  maximum  or  estimated  values  of  the  corresponding  patients.
‡Group  2:  Patients  who  continued  oral  corticosteroids  for  ≥6  months  after  discharge  or  whose  FEV1  was  maintained  at  <60%. 
§Group  1  vs.  Group  2
Table  1.  Demographic  features  and  past  history  of  the  enrolled  patients
Numerous  studies  have  concluded  that  NFA  is  a  major  risk 
factor  for  asthma-related  deaths.  A  clinical  follow-up  study 
conducted  in  1992  reported  that  the  mortality  rates  of  patients 
who  required  mechanical  ventilation  were  10.1%  after  1  year, 
14.4% after 3 years, and 22.6% after 6 years
5). According to a 
more  recent  study,  however,  the  mortality  rate  for  asthma 
tended  to  decrease  over  time,  and  because  many  patients 
r e c o v e r  f r o m  N F A ,  i t  i s  i m p o r t a n t  t o  a n a l y z e  t h e  p r o g n o s t i c  
factors  that  may  affect  the  clinical  outcomes  in  these  patients 
after  discharge  from  the  hospital
6).
Several  studies  have  been  conducted  on  NFA  risk  factor 
determination,  but  few  conclusive  reports  exist  on  NFA  risk 
f o l l o w - u p .  T h e  a i m  o f  t h i s  s t u d y  w a s  t o  i d e n t i f y  p r o g n o s t i c  
factors  related  to  NFA  patient  outcomes.  We  compared  NFA 
patients who required continual oral corticosteroid administration 
or  had  irreversible  airway  obstructions  and  those  who  did  not 
require  prolonged  steroid  therapy  or  had  reversible  airflow 
obstructions. 
MATERIALS AND METHODS
Study  subjects
We  enrolled  and  analyzed  68  asthmatic  patients  who  were 
treated  at  the  intensive  care  units  (ICUs)  of  five  university 
hospitals  located  in  Seoul  and  Kyounggi  Province.  In  accor-
dance  with  the  National  Asthma  Education  and  Prevention 
Program Expert Panel Report 2 of the U.S. National Institutes of 
Health  and  the  criteria  suggested  by  the  BTS,  severe  asthma 
exacerbation  was defined  as  an  attack characterized  by  one  of 
the  following:  absence  of  respiratory  sounds,  bradycardia, 
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  All Group  1 Group  2 p v a l u e
†
Duration  of  exacerbations 
  < 4  h  
    4-24  h 
    1-7  days 
  > 7  d a y s
Aggravating  factors
  Infectious  diseases
    P n e u m o n i a  
    NSAIDs  exposure 
  U n k n o w n
Cardiac  problems
Total  duration  of  admission
  < 1  w k
    1-2  wk
  > 2  w k
ICU  admission,  days
Mechanical  ventilation 
  D u r a t i o n ,  d a y s
14  (20.6)
25  (36.8)
24  (35.3)
5  (7.4)
52  (76.5)
28  (41.2)
5  (7.4)
8  (11.8)
12  (17.9)
18  (26.5)
28  (41.2)
22  (32.4)
5.60±0.88
43  (63.2)
3.18±0.82
5  (15.6)
11  (34.4)
14  (43.8)
2  (6.3)
22  (68.8)
9  (28.1)
4  (12.5)
3  (9.4)
3  (9.4)
10  (31.3)
17  (53.1)
5  (15.6)
3.78±0.47
18  (56.3)
3.22±0.64
9  (25.0)
14  (38.9)
10  (27.8)
3  (8.3)
30  (83.3)
19  (52.8)
1  (2.8)
5  (13.9)
9  (25.7)
8  (22.2)
11  (30.6)
17  (47.2)
7.22±1.57
25  (69.4)
6.32±2.02
NS
 
 
 
NS
0.039
NS
NS
0.081
 
0.020
0.042
NS
NS
*Values  given  as  means±SE  or  No.  (%),  unless  otherwise  indicated.  NSAIDs, nonsteroidal  anti-inflammatory  drugs;  NS, not 
significant.
†Group  1  vs.  Group  2
Table  2.  Clinical  characteristics  of  the  patients  during  hospitalization
respiratory  arrest,  or  the  need  for  tracheal  intubation
3, 7).  All 
patients had regular follow-up examinations for at least 6 months 
following  hospital  discharge.  Patients  with  a  smoking  history  of 
more than 10 pack-years and those with pulmonary emphysema 
confirmed by chest radiography or computed tomography were 
excluded  from  this  study  owing  to  the  possibility  of  underlying 
chronic  obstructive  pulmonary  disease. 
The patients were divided into two groups. For the patients in 
Group 1, oral corticosteroids were discontinued within 6 months 
after hospital discharge and the forced expiratory volume in 1 s 
(FEV1)  was  maintained  ≥60%  of  the  maximum  or  estimated 
values  of  the  corresponding  patients.  For  the  patients  in  Group 
2, oral corticosteroids were administered for ≥6 months or the 
FEV1  was  maintained  at  <60%. 
Data  collection
We analyzed the patients’ medical records to collect data on 
demographic  characteristics,  previous  asthma  history,  atopy, 
smoking  status,  clinical  features  during  hospitalization,  and 
outpatient clinic follow-ups after hospital discharge. Asthma history 
included  the  duration  of  asthma,  previous  asthma-related 
hospitalizations,  and  a  list  of  administered  anti-asthmatic  agents. 
Hospitalization  for  asthma  was  categorized  as  admission  to  the 
ICU  or  to  the  general  ward.  We  documented  the  types  of 
anti-asthmatic agents that were administered at 3 months and 2 
weeks  prior  to  the  asthma-related  hospitalizations. 
Atopy  was  assessed  in  patients  with  a  history  of  allergic 
rhinitis or atopic dermatitis, as determined by a positive reaction 
on  a  skin  prick  test  or  the  presence  of  serum  specific  IgE.  To 
analyze the clinical characteristics, we examined the duration of 
dyspnea  before  hospitalization,  potential  aggravating  factors, 
length  of  the  hospital  or  ICU  stay,  duration  of  mechanical 
ventilation  assistance,  and  vital  signs  at  the  time  of  admission. 
Laboratory findings and chest radiographs at the initial visit were 
analyzed.  Follow-up  duration,  post-discharge  duration  of  oral 
corticosteroid  administration,  and  asthma-related  rehospitali-
zations  were  assessed  for  each  patient. 
Statistical  analysis
T h e  d a t a  a r e  e x p r e s s e d  a s  me a n s ±s t a n d a r d  e r r or  ( S E ) .  T h e  
statistical analyses were performed using SPSS software, version 
12.0  (SPSS  Inc.,  Chicago,  IL,  USA). For  continuous  variables,  we 
compared  the  independent  groups  using  Student’s  t-test.  The 
relationship  between  categorical  variables  was  assessed  using  X
2 
analysis.  A  value  of  p<0.05  was  considered  to  be  statistically 
significant.
RESULTS
Demographic  characteristics  and  past  history
Table  1  shows  the  patients’  demographic  features  and 
histories.  The  mean  age  differed  significantly  between  the  two 
groups  (Group  1  vs.  Group  2:  48.47±3.53  vs.  64.69±2.59 
years;  p<0.05).
T h e  p a t i e n t s  i n  G r o u p  2  h a d  a s t h m a  f o r  a  l o n g e r  t i m e  t h a n  Myung-Shin  Kim,  et  al.  Near-fatal  asthma  and  prognostic  factors 173
All Group  1 Group  2 p v a l u e
†
Physical  examination
    sBP,  mmHg
    dBP,  mmHg
  P R ,  / m i n
  R R ,  / m i n
Laboratory  findings
  A r t e r i a l  p H  
  P a C O 2,  mmHg 
  P a O 2,  mmHg
  W B C ,  c e l l s /
  E S R ,  m m / h
  C R P ,  m g / d L
  A l b u m i n ,  g / d L
137.92±5.06
82.42±3.08
112.85±3.43
28.03±1.18
7.25±0.02
59.14±3.88
71.20±4.67
14571±808
17.98±3.01
4.64±1.03
3.74±0.09
137.19±6.08
82.29±3.90
114.10±3.18
27.52±1.49
7.224±0.031
62.10±6.67
71.28±4.95
13863±831
8.75±2.05
1.72±0.46
4.00±0.14
138.59±8.02
82.53±4.76
111.71±5.94
28.50±1.82
7.277±0.031
56.45±4.30
71.14±7.79
15200±1340
23.88±4.40
6.68±9.36
3.51±0.10
NS
NS
NS
NS
NS
NS
NS
NS
0.004
0.006
0.005
*Values  given  as  means±SE.  sBP, systolic  blood  pressure;  dBP, diastolic  blood  pressure;  PR, pulse  rate;  RR, respiratory  rate; 
ABGA, a r t e r i a l  b l o o d  g a s  a n a l y s i s ;  W B C ,  w h i t e  b l o o d  c e l l ;  E S R ,  erythrocyte  sedimentation  rate;  CRP, C-reactive  protein;  NS, not 
significant.
†Group  1  vs.  Group  2
Table  3.  Physical  examination  and  laboratory  findings
All Group  1 Group  2 p v a l u e
†
F o l l o w  u p ,  m o
Readmission 
  E D ,  G W  < 3  d a y s  
  G W  > 3  d a y s  
  I C U
OCS  dosage  after  discharge,  mg/day
  < 1  w k
    1  wk  to  1  mo
    1  mo  to  3  mo
    3  mo  to  6  mo
    Average 
30.21±3.38
21  (36.2)
5  (8.6)
15  (25.9)
5  (8.6)
19.43±2.29
9.47±1.19
4.39±0.96
5.22±1.29
5.32±0.80
28.88±4.96
8  (23.5)
3  (8.8)
5  (14.7)
0  (0)
20.10±3.28
8.05±1.52
1.27±0.37
2.03±1.89
2.84±0.78
31.92±4.46
13  (54.2)
2  (8.3)
10  (41.7)
5  (20.8)
18.53±3.15
11.35±1.85
7.76±1.73
8.27±7.84
8.39±1.29
NS
NS
NS
0.021
0.005
NS
NS
0.001
0.014
0.001
*V a l u e s  g i v e n  a s  m e a n s ± S E  o r  N o .  ( % ) ,  u n l e s s  o t h e r w i s e  i n d i c a t e d .  ED, emergency  department;  GW, general  ward;  ICU, intensive 
care  unit;  OCS, oral  corticosteroid;  NS, not  significant.
†Group  1  vs.  Group  2
Table  4.  Clinical  outcome  and  prognosis  of  discharged  patients
those in Group 1 (>10 years in Group 2), but the difference was 
not statistically significant (Group 1 vs. Group 2: 21.9 vs. 38.9%, 
p >0. 05) .  Compa r e d wi t h Gr oup 1,  Gr oup 2 wa s  t r e a t e d mor e 
frequently  with  anti-inflammatory  agents  before  ICU  admission 
(Group 1 vs. Group 2: 18.8 vs. 47.2%, p<0.05), especially with 
respect  to  oral  corticosteroids  during  the  3  months  before 
admission and inhaled corticosteroids during the 2 weeks before 
admission (Group 1 vs. Group 2: 9.4 vs. 36.1%,  p=0.009; and 
15.6  vs.  38.9%,  p<0.05,  respectively).  In  Group  1,  five  of  the 
nine  patients  who  had  received  inhaled  corticosteroids  for  3 
months before hospitalization stopped taking the drugs 2 weeks 
before  hospitalization.  Both  study  groups  used  β-agonists  with 
similar  frequency. 
Clinical  characteristics  during  hospitalization
The  clinical  characteristics  of  the  study  patients  during 
hospitalization  are  summarized  in  Table  2,  and  the  physical 
f i n d i n g s  a n d  l a b o r a t o r y  t e s t  r e s u l t s  a r e  r e p o r t e d  i n  T a b l e  3 .  
Based  on  chest  radiography,  pneumonia  occurred  more 
f r e q u e n t l y  i n  G r o u p  2  t h a n  i n  G r o u p  1  ( G r o u p  1  v s .  G r o u p  2 :  
28.1 vs. 52.8%, p<0.05), with concomitantly longer hospital (≥2 
weeks)  and  ICU  stays  by  the  Group  2  patients  (Group  1  vs. 
Group  2:  15.6  vs.  47.2%,  p<0.05;  and  3.78±0.47  vs. 
7.22±1.59 days, p<0.05, respectively). There was no difference 
in  the  degree  of  hypercapnia  between  the  two  groups.  The 
erythrocyte  sedimentation  rate  (ESR)  and  C-reactive  protein 
(CRP) level were significantly higher in Group 2 than in Group 1 
( G r o u p  1  v s .  G r o u p  2 :  8 . l 8 ± 2 . 0 5  v s .  2 3 . 8 8 ± 4 . 4 0  m m / h ,  
p<0.05;  1.72±0.14  vs.  6.68±1.71,  p<0.05,  respectively),  and 
the mean serum albumin level was significantly lower in Group 2 
than  in  Group  1  (Group  1  vs.  Group  2:  4.00±0.14  vs. 
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Follow-up  results
Table 4 presents the data on patient rehospitalization and use 
of  or a l  c or t i c os t e r oi ds .  Compa r e d wi t h  t he  pa t i e nt s  i n  Gr oup 1, 
more patients in Group 2 were readmitted to the ICU or general 
hospital ward for longer than 3 days (41.7%, p<0.05; or 20.8%, 
p<0.05,  respectively).  There  was  no  significant  difference  in  the 
o r a l  c o r t i c o s t e r o i d  d o s a g e  b e t w e e n  t h e  t w o  g r o u p s  d u r i n g  t h e  
first month following hospital discharge, but the dosage differed 
significantly between the groups at the 3- and 6-month follow-up 
visits  (Group  1  vs.  Group  2:  at  3  months,  1.27±0.37  vs. 
7.76±1.73 mg/day, p<0.05; at 6 months, 2.03±1.89 vs. 8.27± 
7.84  mg/day,  p<0.05).
DISCUSSION
Only  a  few  studies  have  analyzed  the  disease  course  and 
prognosis of NFA. In the present study, our aim was to establish 
risk  factors  that  may  influence  the  prognosis  of  NFA  following 
patient  discharge  from  the  ICU.
We categorized the patients with a poor prognosis (Group 2) 
as  those  with  irreversible  airflow  obstruction  or  those  receiving 
oral  corticosteroids  >6  months  post-discharge  to  maintain 
pulmonary  function.  For  two-thirds  of  the  patients  in  Group  2, 
this  admission  to  the  ICU  was  their  first  visit  to  that  university 
hospital,  making  it  difficult  to  compare  clinical  data  before  and 
after  hospitalization  because  of  a  lack  of  baseline  statistics. 
The  patients  in  Group  2  also  exhibited  older  age,  high  ESR 
and  CRP  values  on  admission,  exacerbation  of  asthma  by 
pneumonia  as  confirmed  by  chest  radiography,  and  serum 
albumin levels at the lower normal limit. The high ESR and CRP 
values  indicate  a  state  of  inflammation,  and  the  low  albumin 
suggests  poor  nutrition;  thus  severe  inflammation  and  relatively 
poor  nutrition  may  have  a  negative  impact  on  the  NFA 
prognosis.  Although  the  mechanisms  through  which  acute 
inflammation may influences a negative asthma outcome are not 
entirely  clear,  a  Severe  Asthma  Research  Program  study  found 
that two-thirds of severe chronic asthmatic patients had a history 
of pneumonia and concluded that pneumonia is the highest risk 
f a c t o r  f o r  t h e  d e v e l o p m e n t  a n d  p o o r  p r o g n o s i s  o f  N F A
8).  One 
study  assessing  comorbid  diseases  related  to  asthma 
exacerbation in patients with difficult-to-treat asthma reported an 
odds ratio of 6.9 for repeated respiratory tract infections, which 
is in agreement with our results
9). Patients with a poor prognosis 
used  anti-inflammatory  drugs  more  frequently  before 
hospitalization,  suggesting  that  they  had  suffered  from  severe 
chronic  asthma.  Although  it  was  not  a  statistically  significant 
finding, patients in our study with a poor prognosis were likely to 
have had asthma for ≥10 years. This suggests that the severity 
and  chronicity  of  asthma  may  be  important  prognostic  factors 
for  NFA.
In contrast, the smoking status and presence of atopy had no 
effect  on  the  NFA  prognosis.  Additionally,  there  was  no 
significant  difference  between  Groups  1  and  2  regarding  a 
history  of  general  hospital  or  ICU  admission  within  the  recent 
year,  although  hospital  and  ICU  admissions  are  known  to  be 
major  risk  factors  for  asthma-related  deaths.  Hypersensitivity  to 
nonsteroidal  anti-inflammatory  drugs  (NSAIDs)  is  a  characteristic 
of  severe  asthma,  and  previous  studies  have  suggested  that 
NSAIDs  also  act  as  etiologic  agents  for  NFA
10).  I n  t h e  p r e s e n t  
study,  the  asthma  symptoms  in  five  patients  were  exacerbated 
after  NSAID  administration;  one  patient  in  the  poor  prognosis 
group (Group 2) suffered from NSAID-induced asthma aggrava-
tion. This result suggests that hypersensitivity to NSAIDs may be 
a  risk  factor  for  severe  asthma  exacerbation  but  may  not  be 
prognostic  for  NFA.
Prognosis was not significantly correlated with hypercapnea or 
degree of respiratory acidosis at the initial visit. In one study on 
patients  with  severe  asthma  exacerbation,  12  patients  with 
PaCO2 ≥ 1 0 0  m m H g  a n d  2 7  w i t h  P a C O 2  <100  mmHg  were 
followed for 12 years, and hypercapnea was shown to not be a 
factor  influencing  patient  prognosis
11).  Although  one  study 
reported that increases in PaCO2 and acidity were risk factor for 
death, the patients in that study died of septicemia or the failure 
o f  o r g a n s  o t h e r  t h a n  t h e  l u n g s
12).
A  previous  6-year  follow-up  study  on  145  asthma  patients 
with  severe  asthma  exacerbation,  who  died  during  or  after 
hospitalization, suggested that old age is an important NFA risk 
factor,  whereas  hypersensitivity  to  NSAIDs  and  smoking  are  is 
not
6).  This  result  is  similar  to  our  findings. 
In  a  study  based  on  a  cohort  of  the  European  Network  for 
Understanding  Mechanisms  of  Severe  Asthma,  researchers 
compared patients who had developed NFA within 5 years prior 
to  study  entry  with  those  who  had  experienced  no  near-fatal 
asthma attack within the same period. In this comparative study, 
the  NFA  patients  used  more  β-agonists  and  fewer  inhaled 
corticosteroids,  suggesting  that  patient  compliance  with  the 
anti-inflammatory  drug  prescription  is  an  important  prognostic 
factor
13). 
I n  s u m m a r y ,  i n  N F A  p a t i e n t s ,  o l d  a g e ,  s e v e r e  i n f l a m m a t i o n ,  
asthma  exacerbation  by  pneumonia,  relatively  low  nutritional 
status,  and  chronic  severe  asthma  may  be  factors  indicating  a 
poor  prognosis  for  irreversible  obstruction  of  the  airways  with 
subsequent  acute  exacerbation  of  asthma  and  suggesting  the 
need for regular oral corticosteroids following hospital discharge. 
It  is  recommended  that  patients  with  these  risk  factors  be 
treated  appropriately,  under  close  surveillance. Myung-Shin  Kim,  et  al.  Near-fatal  asthma  and  prognostic  factors 175
ACKNOWLEDGMENT 
This study was supported by a grant of the Korea Healthcare 
technology R & D Project, Ministry for Health, Welfare and Family 
Affairs,  Republic  of  Korea.
REFERENCES
 1) Eder W, Ege MJ, von Mutis E. The asthma epidemic. N Engl J Med 
355:2226-2235,  2006
  2) Global  Initiative  for  Asthma  (GINA).  Global  strategy  for  asthma 
management  and  prevention:  NHLBI/WHO  workshop  report. 
Bethesda,  National  Institutes  of  Health,  National  Heart,  Lung  and 
Blood  Institute,  2005
  3) British  Thoracic  Society.  The  British  guidelines  of  asthma  manage-
ment  1995  review  and  position  statement.  Thorax  52:S1-20,  1997
 4) Mun JS, Choi IS, Sim MK. Recent trend in prevalence and severity 
of  acute  asthma  in  an  emergency  room.  Asthma  Allergy  Clin 
Immunol  25:284-290,  2005
  5) Marquette CH, Saulnier F, Leroy O, Wallaert B, Chopin C, Demarcq 
JM,  Durocher  A,  Tonnel  AB.  Long-term  prognosis  of  near-fatal 
asthma:  a  6-year  follow-up  study  of  145  asthmatic  patients  who 
underwent  mechanical  ventilation  for  a  near-fatal  attack  of  asthma. 
Am  Rev  Respir  Dis  146:76-81,  1992
  6) Stow  PJ,  Picher  DV,  Wilson  J,  George  C,  Bailey  M,  Higlett  T, 
Bellomo R, Hart GK. Improved outcomes from acute severe asthma 
in  Australian  intensive  care  units  (1996-2003).  Thorax  62:842-847, 
2007
  7) National  Institutes  of  Health.  National  asthma  education  and 
prevention  program  expert  panel  report:  2.  guidelines  for  diagnosis 
and  management  for  asthma.  NIH  publication  No  97-4051A,  1997
  8) Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes 
BT,  Bacharier  L,  Calhoun  WJ,  Castro  M,  Chung  KF,  Clark  MP, 
Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NM, 
Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, 
Busse  WW,  Wenzel  SE.  Characterization  of  the  severe  asthma 
phenotype by the National Heart, Lung, and Blood Institute's Severe 
Asthma  Research  Program.  J  Allergy  Clin  Immunol  119:405-413, 
2007
  9) Ten  Brinke  A,  Sterk  PJ,  Masclee  AA,  Spinhoven  P,  Schmidt  JT, 
Zwinderman  AH,  Rabe  KF,  Bel  EH.  Risk  factor  of  frequent 
exacerbations  in  difficult-to-treat  asthma.  Eur  Respir  J  26:812-818, 
2005
10) Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A, 
Arakawa M, Yoshizawa H, Gejyo F. Contribution of aspirin- intolerant 
asthma  to  near  fatal  asthma  based  on  a  questionnaire  survey  in 
Niigata  prefecture,  Japan.  Respirology  10:477-484,  2005
11) Wasserfallen  JB,  Leuenberger  P,  Schaller  MD,  Perret  C.  Extreme 
hypercapnea  is  not  a  long-term  prognostic  factor  after  near-fatal 
asthma:  a  12-year  follow-up  study.  Schweiz  Med  Wochenschr 
128:323-330,  1998
12) Afessa  B,  Morales  I,  Cury  JD.  Clinical  course  and  outcome  of 
patients admitted to an ICU for status asthmaticus. Chest 120:1616- 
1621,  2001
13) Romagnoli  M,  Caramori  G,  Braccinoi  F,  Ravenna  F,  Barreiro  E, 
Siafakas NM, Vignola AM, Chanez P, Fabbri LM, Papi A. Near-fatal 
asthma  phenotype  in  the  ENFUMOSA  Cohort.  Clin  Exp  Allergy 
37:552-557,  2007